Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells

Journal of Clinical Investigation

Volumn 126, Issue 11, 2016, Pages 4174-4186

  Shenoy, Anitha K ^a,b   Jin, Yue ^a   Luo, Huacheng ^a   Tang, Ming ^a   Pampo, Christine ^a   Shao, Rong ^c   Siemann, Dietmar W ^a   Wu, Lizi ^d   Heldermon, Coy D ^d   Law, Brian K ^a   Chang, Lung Ji ^d   Lu, Jianrong ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b California Health Sciences University   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d Department of Molecular Genetics and Microbiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE; SHORT HAIRPIN RNA; TAMOXIFEN; VASCULAR CELL ADHESION MOLECULE 1; VIMENTIN; CADHERIN; CDH2 PROTEIN, HUMAN; CDH2 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; PDGFRB PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; BREAST EPITHELIUM CELL; CANCER CELL; CANCER LOCALIZATION; CANCER TRANSPLANTATION; CELL ADHESION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PERICYTE; PERIVASCULAR SPACE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; A-549 CELL LINE; ANIMAL; MCF-7 CELL LINE; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

A549 CELLS; ANIMALS; ANTIGENS, CD; BIOMARKERS, TUMOR; CADHERINS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MCF-7 CELLS; MICE; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 84994665921     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86623     Document Type: Article

References (66)

1. Harris TJ, Tepass U. Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol. 2010;11(7):502-514
2. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154(1):8-20
3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-1428
4. Trimboli AJ, et al. Direct evidence for epithelialmesenchymal transitions in breast cancer. Cancer Res. 2008;68(3):937-945
5. Yu M, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580-584
6. Zhao Z, et al. In vivo visualization and characterization of epithelial-mesenchymal transition in breast tumors. Cancer Res. 2016;76(8):2094-2104
7. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-890
8. Christofori G. New signals from the invasive front. Nature. 2006;441(7092):444-450
9. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392(6672):190-193
10. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelialmesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell. 2012;22(6):725-736
11. Chui MH. Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step. Int J Cancer. 2013;132(7):1487-1495
12. Bill R, Christofori G. The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett. 2015;589(14):1577-1587
13. Argast GM, et al. Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis. 2011;28(7):593-614
14. Morel AP, et al. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudinlow tumors in transgenic mice. PLoS Genet. 2012;8(5):e1002723
15. Taube JH, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010;107(35):15449-15454
16. Fischer KR, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472-476
17. Zheng X, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525-530
18. Whittle MC, et al. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell. 2015;161(6):1345-1360
19. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-428
20. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178-196
21. Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715
22. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000;92(14):1185-1186
23. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003;23(7):1185-1189
24. Jahn SC, et al. An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Lett. 2012;326(2):183-190
25. Bergers G, Song S. The role of pericytes in bloodvessel formation and maintenance. Neuro-oncology. 2005;7(4):452-464
26. Armulik A, Genové G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193-215
27. Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci. 2011;14(11):1398-1405
28. Díaz-Flores L, et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol. 2009;24(7):909-969
29. Hosaka K, et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat Commun. 2013;4:2129
30. Massagué J. TGFbeta in cancer. Cell. 2008; 134(2):215-230
31. Tang M, et al. The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition. J Biol Chem. 2013;288(38):27680-27691
32. Ozerdem U, Grako KA, Dahlin-Huppe K, Monosov E, Stallcup WB. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn. 2001;222(2):218-227
33. Darland DC, D'Amore PA. TGF beta is required for the formation of capillary-like structures in three-dimensional cocultures of 10T1/2 and endothelial cells. Angiogenesis. 2001;4(1):11-20
34. Bryan BA, D'Amore PA. Pericyte isolation and use in endothelial/pericyte coculture models. Meth Enzymol. 2008;443:315-331
35. Shao R, Guo X. Human microvascular endothelial cells immortalized with human telomerase catalytic protein: a model for the study of in vitro angiogenesis. Biochem Biophys Res Commun. 2004;321(4):788-794
36. Li F, et al. Endothelial Smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with Notch. Dev Cell. 2011;20(3):291-302
37. Gerhardt H, Wolburg H, Redies C. N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Dev Dyn. 2000;218(3):472-479
38. Keogh MC, Chen D, Schmitt JF, Dennehy U, Kakkar VV, Lemoine NR. Design of a muscle cell-specific expression vector utilising human vascular smooth muscle alpha-actin regulatory elements. Gene Ther. 1999;6(4):616-628
39. Brockschnieder D, Lappe-Siefke C, Goebbels S, Boesl MR, Nave KA, Riethmacher D. Cell depletion due to diphtheria toxin fragment A after Cre-mediated recombination. Mol Cell Biol. 2004;24(17):7636-7642
40. Ivanova A, Signore M, Caro N, Greene ND, Copp AJ, Martinez-Barbera JP. In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A. Genesis. 2005;43(3):129-135
41. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn. 1995;202(4):325-332
42. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307
43. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160(3):985-1000
44. Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol. 2010;85(8):593-598
45. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674
46. Dang DT, et al. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res. 2008;68(6):1872-1880
47. Cooke VG, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21(1):66-81
48. van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 2015;67(2):441-461
49. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283-1316
50. Campbell CI, Moorehead RA. Mammary tumors that become independent of the type I insulinlike growth factor receptor express elevated levels of platelet-derived growth factor receptors. BMC Cancer. 2011;11:480
51. Jechlinger M, et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003;22(46):7155-7169
52. Jechlinger M, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 2006;116(6):1561-1570
53. Steller EJ, et al. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia. 2013;15(2):204-217
54. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymallike non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008;25(8):843-854
55. van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14(2):121-134
56. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121(Pt 6):727-735
57. Lugassy C, et al. Pericytic-like angiotropism of glioma and melanoma cells. Am J Dermatopathol. 2002;24(6):473-478
58. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232(2):165-177
59. Cheng L, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013;153(1):139-152
60. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3(6):411-421
61. Ricci-Vitiani L, et al. Tumour vascularization via endothelial differentiation of glioblastoma stemlike cells. Nature. 2010;468(7325):824-828
62. Wang R, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829-833
63. Soda Y, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A. 2011;108(11):4274-4280
64. Francescone R, et al. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem. 2012;287(29):24821-24831
65. Dunleavey JM, et al. Vascular channels formed by subpopulations of PECAM1+ melanoma cells. Nat Commun. 2014;5:5200
66. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95(25):14863-14868